Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®

Neurol Ther. 2018 Dec;7(2):391-393. doi: 10.1007/s40120-018-0116-x. Epub 2018 Nov 10.
No abstract available

Keywords: Bioequivalence; Copemyl®; Equivalence trials; Glatiramer acetate; Glatiramoid; Multiple sclerosis; Non-biological complex drugs.

Publication types

  • Letter